CrossRef BIOTECHNOLOGY AND BIOENGINEERING INNOVATIONS IN PRECISION OBESITY MANAGEMENT: MECHANISTIC INSIGHTS, EMERGING PLATFORMS, AND TRANSLATIONAL PATHWAYS MIN HO HAN, YOUN SEON HWANG, DO HYEON JIN, JIN WOO KIM Journal of Mechanics in Medicine and Biology.2026;[Epub] CrossRef A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass Federica Moscucci, Francesco Baratta, Daniele Pastori, Danilo Menichelli, Anna Vittoria Mattioli, Sabina Gallina, Ilaria Lospinuso, Susanna Sciomer, Gianfranco Piccirillo, Giovambattista Desideri Nutrients.2026

Option Cagrilintide Evidence for the added compound Human Phase 2 data alone and Phase 3 data with semaglutide Evidence for the retatrutide combination None identified Option Tesamorelin Evidence for the added compound Randomized trials and an FDA-approved narrow indication Evidence for the retatrutide combination None identified Option CJC-1295 + ipamorelin Evidence for the added compound Small human studies showing GH or IGF-1 response Evidence for the retatrutide combination None identified Option MOTS-C Evidence for the added compound Human observational biology plus mostly preclinical treatment research Evidence for the retatrutide combination None identified This ranking describes research depth
These findings add further support to a growing body of evidence that suggests that Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) may modulate the human reward system by interacting with receptors in brain regions associated with dopamine signaling
September 2025: Bachem AG expanded its peptide synthesis services for custom therapeutic peptides, integrating continuous-flow solution-phase synthesis to improve yield and scalability
G., Ostojic, S
Hormone Balance and Detox Pathways Your hormones dont work in isolation, theyre processed through the liver, filtered by the gut, and influenced by your antioxidant levels